Live Breaking News & Updates on Orilissa Oriahnn

Stay updated with breaking news from Orilissa oriahnn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AbbVie Reports First-Quarter 2021 Financial Results


- Reports First-Quarter Diluted EPS of $1.99 on a GAAP Basis; Adjusted Diluted EPS of $2.95
- Delivers First-Quarter Net Revenues of $13.010 Billion on a GAAP Basis, an Increase of 51.0 Percent on a Reported Basis; Adjusted Net Revenues Were $12.935 Billion
- First-Quarter Global Net Revenues from the Immunology Portfolio Were $5.744 Billion, an Increase of 12.9 Percent on a Reported Basis, or 11.8 Percent on an Operational Basis; U.S. Humira Net Revenues Were $3.907 Billion, an Increase of 6.9 Percent; Internationally, Humira Net Revenues Were $960 Million, a Decrease of 8.3 Percent on a Reported Basis, or 12.6 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $574 Million; Global Rinvoq Net Revenues Were $303 Million ....

United States , Alphagan Combigan , Linzess Constella , Richarda Gonzalez , Lumigan Ganfort , Orilissa Oriahnn , Boehringer Ingelheim , Caribou Biosciences Inc , Other Women Health , Abbvie Inc , Committee For Medicinal Products Human Use , Drug Administration , Women Health , European Commission , Exchange Commission , European Medicines Agency , American Academy Of Neurology , Roche Group , Botox Cosmetic , Botox Therapeutic , Key Product Revenues , Adapted Mayo Score , New Drug Applications , Prescription Drug User Fee Act , Medicinal Products , Human Use ,